Altimmune's Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification

Altimmune Inc reported a net loss of $27.4 million in Q4 2025, up from $23.2 million in Q4 2024. R&D expense decreased to $18.4 million, while G&A expense increased to $10.5 million. The company completed a $75 million capital raise and has a pro forma cash position of approximately $340 million. Altimmune anticipates a longer operating cash runway, extending into 2028. The FDA granted Breakthrough Therapy designation for pemvidutide in MASH, a significant improvement over existing therapies.